Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Upgraded by StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

Separately, HC Wainwright restated a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

ORMP stock traded up $0.05 during trading on Wednesday, reaching $2.40. 334,565 shares of the company were exchanged, compared to its average volume of 139,023. The stock’s 50 day moving average price is $2.37 and its 200 day moving average price is $2.39. Oramed Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $3.67. The company has a market cap of $96.75 million, a P/E ratio of 21.82 and a beta of 1.70.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. XTX Topco Ltd grew its holdings in shares of Oramed Pharmaceuticals by 59.7% during the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after buying an additional 9,242 shares in the last quarter. Murchinson Ltd. grew its position in shares of Oramed Pharmaceuticals by 0.5% in the third quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock valued at $4,170,000 after purchasing an additional 8,889 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Oramed Pharmaceuticals in the third quarter valued at $272,000. BML Capital Management LLC boosted its stake in Oramed Pharmaceuticals by 62.1% in the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock worth $5,334,000 after buying an additional 837,153 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after buying an additional 108,700 shares during the last quarter. 12.73% of the stock is owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.